Disc Medicine, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Disc Medicine, Inc. (IRON) reported Net Income (Loss) Available to Common Stockholders, Basic of -$26.60 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-12
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$26.60M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$26.35M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$26.95M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$23.58M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$76.43M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$46.83M.
- Disc Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$35.97M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$26.60M 10-Q · filed 2024-11-12 | -$52.95M derived: sum of 2 quarters · filed 2024-11-12 | -$79.90M 10-Q · filed 2024-11-12 | -$103.48M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | -$26.35M 10-Q · filed 2024-08-08 | -$53.30M 10-Q · filed 2024-08-08 | -$76.88M derived: sum of 3 quarters · filed 2024-08-08 | -$91.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | -$26.95M 10-Q · filed 2024-05-09 | -$50.53M derived: sum of 2 quarters · filed 2024-05-09 | -$64.65M derived: sum of 3 quarters · filed 2024-11-12 | -$80.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$23.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$37.70M derived: sum of 2 quarters · filed 2024-11-12 | -$53.65M derived: sum of 3 quarters · filed 2024-11-12 | -$76.43M 10-K · filed 2024-03-21 |
| 2023-09-30 | -$14.12M 10-Q · filed 2024-11-12 | -$30.07M derived: sum of 2 quarters · filed 2024-11-12 | -$52.85M 10-Q · filed 2024-11-12 | -$64.09M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$15.95M 10-Q · filed 2024-08-08 | -$38.73M 10-Q · filed 2024-08-08 | -$49.97M derived: sum of 3 quarters · filed 2024-08-08 | -$66.12M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$22.78M 10-Q · filed 2024-05-09 | -$34.02M derived: sum of 2 quarters · filed 2024-05-09 | -$50.17M derived: sum of 3 quarters · filed 2024-05-09 | -$59.76M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$11.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$27.39M derived: sum of 2 quarters · filed 2024-03-21 | -$36.97M derived: sum of 3 quarters · filed 2024-03-21 | -$46.83M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$16.15M 10-Q · filed 2023-11-09 | -$25.73M derived: sum of 2 quarters · filed 2023-11-09 | -$35.58M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$9.58M 10-Q · filed 2023-08-11 | -$19.43M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$9.85M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$35.97M 10-K · filed 2023-03-31 | |||
| 2021-06-30 | -$16.45M 10-Q · filed 2021-08-12 | -$35.49M 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | -$19.05M 10-Q · filed 2021-05-13 | |||
| 2020-06-30 | -$6.77M 10-Q · filed 2021-08-12 | -$16.52M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$9.75M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |